participating institutions:
Johns Hopkins University AIDS Service, New York State DOH AIDS Institute, The CORE Center, Cook County Hospital



ADULT AND ADOLESCENT ART

last updated: January 28, 2000


COMPLETE GUIDELINES:


html pdf selected tables panel members


RELATED INFORMATION:


faqsnewslinks


ANTIRETROVIRAL PREGNANCY REGISTRY

The Antiretroviral Pregnancy Registry is an epidemiologic project to collect observational, nonexperimental data on antiretroviral exposure during pregnancy for the purpose of assessing the potential teratogenicity of these drugs. Registry data will be used to supplement animal toxicology studies and assist clinicians in weighing the potential risks and benefits of treatment for individual patients. The registry is a collaborative project of the pharmaceutical manufacturers with an advisory committee of obstetric and pediatric practitioners.

It is strongly recommended that health care providers who are treating HIV-1-infected pregnant women and their newborns report cases of prenatal exposure to antiretroviral drugs (either alone or in combination) to the Antiretroviral Pregnancy Registry. The registry does not use patient names, and birth outcome follow-up is obtained by registry staff from the reporting physician. Referrals should be directed to Antiretroviral Pregnancy Registry, 1410 Commonwealth Drive, Wilmington, NC 28403; telephone (800)-258-4263; fax (800) 800-1052.

References

  1. Ayers KM, Clive D, Tucker WE, Jr., Hajian G, de Miranda P. Nonclinical toxicology studies with zidovudine: genetic toxicity tests and carcinogenicity bioassays in mice and rats. Fundam Appl Toxicol 1996;32:148-158
  2. Olivero OA, Anderson LM, Diwan BA, Haines DC, Harbaugh SW, Moskal TJ, Jones AB, Rice JM, Riggs CW, Logsdon D, Yuspa SH, Poirier MC. Transplacental effects of 3'-azido-2',3'-dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys. J Natl Cancer Inst 1997;89:1602-1608
  3. Ayers KM, Torrey CE, Reynolds DJ. A transplacental carcinogenicity bioassay in CD-1 mice with zidovudine. Fundam Appl Toxicol 1997;38:195-198
  4. Reggy AA, Rogers MF, Simonds RJ. Using 3'-azido-2',3'-dideoxythymidine (AZT) to prevent perinatal human immunodeficiency virus transmission and risk of transplacental carcinogenesis. J Natl Cancer Inst 1997;89:1566-1567
  5. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, VanDyke R, Bey M, Shearer W, Jacobson RL, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994;331:1173-1180
  6. Hanson IC, Antonelli TA, Sperling RS, Oleske JM, Cooper E, Culnane M, Fowler MG, Kalish LA, Lee SS, McSherry G, Mofenson L, Shapiro DE. Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine. J Acquir Immune Defic Syndr Hum Retrovirol 1999;20:463-467
  7. Toltzis P, Marx CM, Kleinman N, Levine EM, Schmidt EV. Zidovudine- associated embryonic toxicity in mice. J Infect Dis 1991;163:1212-1218
  8. Antiretroviral pregnancy registry. PharmaResearch Corp., Wilmington, NC. January 1989 - July 1997
  9. Sperling RS, Shapiro DE, McSherry GD, Britto P, Cunningham BE, Culnane M, Coombs RW, Scott G, Van Dyke RB, Shearer WT, Jimenez E, Diaz C, Harrison DD, Delfraissy JF. Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 Study. AIDS 1998;12:1805-1813
  10. White A, Eldridge R, Andrews E. Birth outcomes following zidovudine exposure in pregnant women: the Antiretroviral Pregnancy Registry. Acta Paediatr Suppl 1997;421:86-88
  11. O'Sullivan MJ, Boyer PJ, Scott GB, Parks WP, Weller S, Blum MR, Balsley J, Bryson YJ. The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Zidovudine Collaborative Working Group. Am J Obstet Gynecol 1993;168:1510-1516
  12. Bardeguez AD, Mofenson LM, Spino C, Shapiro DE, Fowler MG, Sperling R, and Boyer R. Lack of clinical and immunologic disease progression with transient use of zidovudine (zdv) to reduce perinatal HIV-1 transmission in PACTG 076. In: 12th World Conference on AIDS. Geneva:, 1998 (abstract 12233).
  13. Culnane M, Fowler M, Lee SS, McSherry G, Brady M, O'Donnell K, Mofenson L, Gortmaker SL, Shapiro DE, Scott G, Jimenez E, Moore EC, Diaz C, Flynn PM, Cunningham B, Oleske J. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. J Am Med Assoc 1999;281:151-157
  14. Toltzis P, Mourton T, Magnuson T. Comparative embryonic cytotoxicity of antiretroviral nucleosides. J Infect Dis 1994;169:1100-1102
  15. Wang Y, Livingston E, Patil S, et al. Pharmacokinetics of didanosine in antepartum and postpartum human immunodeficiency virus-infected pregnant women and their neonates: an AIDS Clinical Trials Group study. J Infect Dis 1999;180:1536-1541.
  16. Moodley J, Moodley D, Pillay K, Coovadia H, Saba J, van Leeuwen R, Goodwin C, Harrigan PR, Moore KH, Stone C, Plumb R, Johnson MA. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis 1998;178:1327-1333
  17. Odinecs A, Nosbisch C, Keller RD, Baughman WL, Unadkat JD. In vivo maternal-fetal pharmacokinetics of stavudine (2',3'-didehydro- 3'- deoxythymidine) in pigtailed macaques (Macaca nemestrina). Antimicrob Agents Chemother 1996;40:196-202
  18. Odinecs A, Pereira C, Nosbisch C, Unadkat JD. Prenatal and postpartum pharmacokinetics of stavudine (2',3'-didehydro- 3'-deoxythymidine) and didanosine (dideoxyinosine) in pigtailed macaques (Macaca nemestrina). Antimicrob Agents Chemother 1996;40:2423-2425
  19. Sandberg JA, Binienda Z, Lipe G, Rose LM, Parker WB, Ali SF, Slikker W, Jr. Placental transfer and fetal disposition of 2',3'-dideoxycytidine and 2',3'-dideoxyinosine in the rhesus monkey. Drug Metab Dispos 1995;23:881-884
  20. Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998;12:1735-1744
  21. Martin JL, Brown CE, Matthews-Davis N, Reardon JE. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob Agents Chemother 1994;38:2743-2749
  22. Blanche S, Tardieu M, Rustin P, Slama A, Barret B, Firtion G, Ciraru-Vigneron N, Lacroix C, Rouzioux C, Mandelbrot L, Desguerre I, Rotig A, Mayaux MJ, Delfraissy JF. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999;354:1084-1089
  23. Smith M, Group USNSRW. Ongoing nucleoside safety review of HIV-exposed children in U.S. studies. In: Second Conference on Global Strategies for the Prevention of HIV Transmission from Mothers to Infants. Montreal, Canada: September 1999 (Abstract 096)
  24. Lange J, Stellato R, al. KBe. Review of neurological adverse events in relation to mitochondrial dysfunction in the prevention of mother to child transmission of HIV: PETRA study. In: Second Conference on Global Strategies for the Prevention of HIV Transmission from Mothers to Infants. Montreal, Canada: September 1999 (Abstract 250)
  25. Morris AA, Carr A. HIV nucleoside analogues: new adverse effects on mitochondria? Lancet 1999;354:1046-1047
  26. Mirochnick M, Fenton T, Gagnier P, Pav J, Gwynne M, Siminski S, Sperling RS, Beckerman K, Jimenez E, Yogev R, Spector SA, Sullivan JL. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1- infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis 1998;178:368-374
  27. Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, Sherman J, Bakaki P, Ducar C, Deseyve M, Emel L, Mirochnick M, Fowler MG, Mofenson L, Miotti P, Dransfield K, Bray D, Mmiro F, Jackson JB. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999;354:795-802 28.
  28. Food and Drug Adminstration Advisory. FDA Public Health Advisory: reports of diabetes and hyperglycemia in patients receiving protease inhibitors for treatment of human immunodeficiency virus (HIV). Food and Drug Administration, Public Health Service, Department of Health and Human Services, Rockville, MD: June 11, 1997.
  29. Visnegarwala F, Krause KL, Musher DM. Severe diabetes associated with protease inhibitor therapy. Ann Intern Med 1997;127:947
  30. Eastone JA, Decker CF. New-onset diabetes mellitus associated with use of protease inhibitor. Ann Intern Med 1997;127:948
  31. Dube M. Metabolic complications of antiretroviral therapies. AIDS Clinical Care 1998;10:41-48.
  32. Lorenzi P, Spicher VM, Laubereau B, Hirschel B, Kind C, Rudin C, Irion O, Kaiser L. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study. AIDS 1998;12:F241-7
  33. Martin R, Boyer P, Hammill H, Peavy H, Platzker A, Settlage R, Shah A, Sperling R, Tuomala R, Wu M. Incidence of premature birth and neonatal respiratory disease in infants of HIV-positive mothers. The Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted Human Immunodeficiency Virus Infection Study Group. J Pediatr 1997;131:851-856
  34. Leroy V, Ladner J, Nyiraziraje M, De Clercq A, Bazubagira A, Van de Perre P, Karita E, Dabis F. Effect of HIV-1 infection on pregnancy outcome in women in Kigali, Rwanda, 1992-1994. Pregnancy and HIV Study Group. AIDS 1998;12:643-650
  35. Brocklehurst P, French R. The association between maternal HIV infection and perinatal outcome: a systematic review of the literature and meta-analysis. Br J Obstet Gynaecol 1998;105:836-848
  36. Casey BM, Bawdon RE. Placental transfer of ritonavir with zidovudine in the ex vivo placental perfusion model. Am J Obstet Gynecol 1998;179:758-761
  37. Chaube S, Murphy ML. The effects of hydroxyurea and related compounds on the rat fetus. Cancer Res 1966;26:1448-1457
  38. Ferm VH. Severe developmental malformations. Arch Pathol 1966;81:174-177
  39. Khera KS. A teratogenicity study on hydroxyurea and diphenylhydantoin in cats. Teratology 1979;20:447-452
  40. Wilson JG, Scott WJ, Ritter EJ, Fradkin R. Comparative distribution and embryotoxicity of hydroxyurea in pregnant rats and rhesus monkeys. Teratology 1975;11:169-178
  41. Aliverti V, Bonanomi L, Giavini E. Hydroxyurea as a reference standard in teratological screening. Comparison of the embryotoxic and teratogenic effects following single intraperitoneal or repeated oral administrations to pregnant rats. Arch Toxicol Suppl 1980;4:239-247
  42. DeSesso JM, Jordan RL. Drug-induced limb dysplasias in fetal rabbits. Teratology 1977;15:199-211
  43. Fritz H, Hess R. Effects of hydroxyurea on postnatal growth and behaviour of rats. Agents Actions 1980;10:389-393
  44. Sylvester RK, Lobell M, Teresi ME, Brundage D, Dubowy R. Excretion of hydroxyurea into milk. Cancer 1987;60:2177-2178
  45. Diav-Citrin O, Hunnisett L, Sher GD, Koren G. Hydroxyurea use during pregnancy: a case report in sickle cell disease and review of the literature. Am J Hematol 1999;60:148-150





Copyright © 2000. The National AIDS Education and Training Centers Program on behalf of its AETC National Resource Center. All rights reserved.

Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained in this site because no single reference or service can take the place of medical training, education, and experience. Consumers are cautioned that this site is not intended to provide medical advice about any specific medical condition they may have or treatment they may need, and they are encouraged to call or see their physician or other health care provider promptly with any health related questions they may have.